logo
Menu

This search function provides links to outputs produced by NIHR Innovation Observatory. These are briefing notes or reports on new or repurposed technologies. This search will not return all technologies currently in development as these outputs are produced as required for our stakeholders.

Innovation Observatory > Reports > Drugs > Setmelanotide for rare genetic obesity due to leptin receptor deficiency

< Back

Setmelanotide for rare genetic obesity due to leptin receptor deficiency

Drugs

May 2019


Setmelanotide is in clinical development for the treatment of rare genetic obesity due to leptin receptor deficiency. The leptin receptor is found on the surface of cells in many organs and tissues of the body, including a part of the brain called the hypothalamus, which controls hunger and thirst. The leptin receptor is involved in the control of body weight by increasing energy expenditure and reducing appetite. Individuals with leptin receptor deficiency experience excessive hunger and weight gain.
Setmelanotide is given as a sub-cutaneous (under the skin) injection. It is believed to restore lost activity of the leptin receptor, re-establishing weight and appetite control in patients. If licensed, setmelanotide will offer a treatment option for patients with obesity due to leptin receptor deficiency who currently have few effective therapies available.

Innovation Observatory Voice 0

Leave a Reply

Your email address will not be published. Required fields are marked *

Post Comment

Download Full Article



 

Connect to the Innovation Observatory

Twitter

Get Alerts